Development

Articles

Characterizing Microstructural Differences of Semisolid Topical Dosage Forms

Topical semi-solids, like creams, lotions and ointments are comprised of a complex mixture of microstructures or colloidal phases, frequently referred to as the Q3. These microstructures may include micelles, lamellar phases, polymer matrices, liquid crystalline and crystalline states of wax excipients, as well as the solid states of active pharmaceutical ingredients. Different topical medicated semi-solid formulations, spanning a range of treatment indications, reveal a variety of different microstructures.

Understanding the Role of Excipients in Topical Semi-Solid Microstructure and Critical Performance Parameters

The company expanded its topicals capacity with an investment in the Becomix RW30 model homogenizer.

Juniper Pharma Services Expands Topicals Capacity

The agency publishes draft guidance on assessing the adhesion of transdermal delivery systems and topical patches.

FDA Releases Guidance on Topical Patches

Agnes Shanley is senior editor of Pharmaceutical Technology.

Quality by design, in-vitro release testing, and modern analytical methods are improving understanding and control of these complex formulations.

Optimizing Semisolid Dosage Forms

The Transform hydrate-able film from Lubrizol LifeSciences is compatible with a range of APIs.

Lubrizol Introduces Topical Film

Dow Corning will also be presenting topical and transdermal technology advances at CPhI.

Dow Corning Showcases Scar and Stretchmark Solutions

Andrew Teasdale, PhD, is a Principle Scientist at AstraZeneca.

Katherine Ulman is a Global Regulatory Compliance Manager at Dow Corning.

Phyllis Walsh is a senior compendial manager at Schering-Plough Corporation in Kenilworth, New Jersey.

EHS specialist at Dow Corning Corporation, Auburn, MI

Current guidance for absorption of elemental impurities does not address dermal exposure, resulting in a simplistic approach to limit setting.

Establishing Limits for Dermal Absorption of Elemental Impurities

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Advanced drug delivery technologies can increase efficacy and safety, extend patent lives, and provide competitive differentiation for biopharmaceuticals.

Drug Delivery Technologies Provide Growth Opportunities for Biopharmaceuticals

Molecular Profiles has secured a major pan-European formulation project, in which the company will be responsible for developing a topical and an oral formulation for Telormedix's psoriasis products, TMX-302.

Formulation and Drug Delivery, Topical Drugs